Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California Florida Cancer Specialist, Sarasota, Florida Washington University School of Medicine, St Louis, Missouri Sarah Cannon Research Center, Nashville, Tennessee NEXT Oncology, San Antonio, Texas NEXT Oncology, Fairfax, Virginia